Nanotechnology-based delivery of therapeutics through the intranasal pathway and the blood–brain barrier for Alzheimer's disease treatment-Reference-Cited by-同舟云学术

Nanotechnology-based delivery of therapeutics through the intranasal pathway and the blood–brain barrier for Alzheimer's disease treatment

Published:2024 Issue:8 Volume:12 Page:2007-2018
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Boyetey Mark-Jefferson Buer¹,Choi Yonghyun¹²,Lee Hee-Young³^ORCID,Choi Jonghoon¹²^ORCID

Affiliation:

1. School of Integrative Engineering, Chung-Ang University, Seoul 06974, Republic of Korea

2. Feynman Institute of Technology, Nanomedicine Corporation, Seoul 06974, Republic of Korea

3. Department of Chemical Engineering, Kumoh National Institute of Technology, 61, Daehak-ro, Gumi-si, Gyeongsangbuk-do 39177, Republic of Korea

Abstract

Drugs for Alzheimer's disease (AD) fail to exhibit efficacy in clinical trials for a number of reasons, a major one being blood–brain barrier (BBB) permeability.

Funder

National Research Foundation of Korea

Korea Environmental Industry and Technology Institute

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/BM/D3BM02003G

Reference96 articles.

1. Aging NIo. , Alzheimer's Disease & Related Dementias: Alzheimer's Disease Fact Sheet [Online] . National Institute of Health , 2023 [updated April 05, 2023. Available from: https://www.nia.nih.gov

2. Cost of Treatment and Care for People with Alzheimer’s Disease: A Meta- Analysis

3. A. Europe , Dementia in Europe Yearbook 2019: Estimating the prevalence of dementia in Europe , Alzheimer Europe , 2019 , p. 180

4. 2022 Alzheimer's disease facts and figures

5. The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review